Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fundamentals on this one are amazing
Yeah, I call that "all steak and no sizzle". That's okay, the steak is the fundamental part.
This company has so much potential upside I really think the biggest problem they have is not relaying to us the investors all the good that is going on.
You as well!
Best of luck to you
I'm going to get some tomorrow finally
I have added more on the weakness
No, didn't have the funds till now actually.
Did you ever get in?
Hope to join you soon
I added more this week
Thanks for answering! This is looking really good. Working on freeing some funds.
Closing of offering announced.
http://www.globenewswire.com/news-release/2021/02/12/2175175/0/en/Enlivex-Announces-Closing-of-Previously-Announced-Bought-Deal-Offering-of-Approximately-46-0-Million-Ordinary-Shares.html http://www.globenewswire.com/news-release/2021/02/12/2175175/0/en/Enlivex-Announces-Closing-of-Previously-Announced-Bought-Deal-Offering-of-Approximately-46-0-Million-Ordinary-Shares.html
Nice Ark added 23k ENLV. 411k shares now
Sepsis would be a $30b total addressable market, where there is not a great treatment right now. Non-covid ARDS would be $15b TAM
Seems way undervalued for how well all trials have gone thus far. Only $330 mil market cap right now.
No don’t think so.
So I'm not too late?
ENLV Covid-19 Treatment. It works.
ENLV Covid-19 Treatment ?? ?? ??
First-time DD post here. The play in Enlivex, or ENLV. Owned by ARK and Cathie has been adding heavy lately. As of February 10, 2021, Ark has 373k shares of ENLV, after adding 37k on Wednesday. ?? ?? ??
ELVN is a biotech company that is developing a drug for sepsis, Allocetra. Allocetra is a drug meant to treat the overreaction of the immune system. So the geniuses at Enlivex thought, hey, maybe this will work for covid-19, by preventing the body from over-reacting and cytokine storm from happening, thus stopping the worst of covid-19. The treatment infuses billions of early apoptotic cells, or dying cells, into the bloodstream. Macrophages and dendritic cells, the body’s first responders, feed on these apoptotic cells, releasing fewer cytokine alert signals and calming the storm. The study drug, Allocetra-OTS, is based on the known activity of apoptotic cells to contribute to maintenance of peripheral immune homeostasis. An altered immune response is associated with organ dysfunction in sepsis, so the possibility is being tested that the study drug can improve the condition of sepsis. Sepsis is a big deal. But first see what it did for covid-19 in Phase Ib and Phase II trials.
Phase II + Ib (21 patients treated)
11/21 (52%) with severe illness10/21 (48%) with critical illness0/21 (0%) mortality on day-28 19/21 (90.5%) patients recovered and were discharged from the hospital by day-28 Average duration of hospitalization post administration of AllocetraTM for discharged patients was 5.6 days 2/21 (9.5%) patients, both of whom had critical illness at the time of AllocetraTM treatment, were hospitalized in the ICU on a respirator on day-28
100% survival rate for severe and critical patients
[https://www.globenewswire.com/news-release/2020/12/03/2139086/0/en/Enlivex-Reports-Positive-Interim-Results-From-Phase-II-Clinical-Trial-Evaluating-Allocetra-in-Severe-and-Critical-COVID-19-Patients.html](https://www.globenewswire.com/news-release/2020/12/03/2139086/0/en/Enlivex-Reports-Positive-Interim-Results-From-Phase-II-Clinical-Trial-Evaluating-Allocetra-in-Severe-and-Critical-COVID-19-Patients.html)
Check out their January 2021 investor presentation here: [https://enlivex.com/wp-content/uploads/2021/01/enlivex-investor-presentation-jan-2021.pdf ](https://enlivex.com/wp-content/uploads/2021/01/enlivex-investor-presentation-jan-2021.pdf)
The investor presentation shows the covid-19 related market size as $1 billion, but the real kicker is if it gets approved for sepsis, because that is a $30 billion market. The sepsis market is 30x that of the covid-19 market. Allocetra has also shown efficacy for sepsis.And $ENLV market cap is only $332 million. Way undervalued with the potential and positive results for Allocetra.
Here is some data from the Phase I trials for sepsis:
The Acute Physiology and Chronic Health Evaluation (APACHEII) score of the AllocetraTM-treated group was 12.9, and the corresponding probability of mortality of at least one patient in that group was predicted at 85% based on the hospital ICU staff’s clinical assessment of that patient’s overall condition at admission. However, none (0%) of the AllocetraTM-treated patients died during the 28-day study period, as compared to 27% mortality in the matched control group during the same 28-day period. Each of the 10 AllocetraTM-treated patients had between 2 to 5 dysfunctional organ systems upon admission to the ICU. All (100%) of the AllocetraTM-treated patients had rapid and complete recovery from their septic conditions and any organ dysfunction that was present upon admission to the ICU. Despite the similar SOFA score at admission between the AllocetraTM-treated patients and the matched controls (average of 3.4 versus 3.47), no AllocetraTM-treated patients had an increase in organ-failure state post AllocetraTM treatment, while the majority of matched controls had an increase in organ-failure state. The average worsening in organ-failure state of patients in the matched control group was approximately 100% compared with their initial ICU hospitalization state vs 0% percent worsening in the organ-failure state of AllocetraTM-treated patients after treatment (p<0.0001). The ICU length-of-stay for all AllocetraTM-treated patients was significantly shorter than those patients who received only the standard of care, with an average of 4.7 days compared to 11.1 days in the matched controls group, a 58% reduction (p<0.0001). The slowest ICU discharge of a patient treated with AllocetraTM was after 8 days, while approximately 50% of the matched controls group remained in the ICU after 21 days.
Another 100% survival rate.
This really seems to be a miracle drug for these diseases.
Positions: March 2021 $25 calls, May 2021 $25 calls, and shares
Not investment advice. Not a financial advisor.
Nice. In big today around $20
Got in Yesterday morning small
Good luck players, doog's movin' on choo-choo>>>$$$$$$$$$$$$$$$$$$$$$$$$$$
haha you don't need one trust me...just keep doing what you're doing and making that bank>>>$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
Thnx again for the a/h's alert friday MG!!!
I sold at $16-18 premarket today lolololol
Maybe you can even gift me a ihub subcription for the tip haha
Yep i made some good money on this one. Premarket went as high as $18 weeeeeeeeeeeeeeeeee
You should've held SM, nutso action ever since a/h's friday>>>ALL ABOARD!!!
Amazing premarket action crude buddy!!! Congratz to everyone who loaded after hours friday choo-choo>>>$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
These are the money makers woot-woot>>>$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
What a beautiful tip MonstaGains gave me on this one after hours friday weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
Enlivex Therapeutics Ltd is an Israel-based clinical-stage company focused on specialized cell immunotherapy. The Company aims to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. The Company is developing Allocetra, a cell-based immunotherapy, for the treatment of numerous acute conditions. It rebalances a life-threatening unbalanced immune system, using the immune system’s own natural regulation mechanisms. Allocetra is designed to avert cytokine storms and restores safe immune balance, without suppressing the immune system, by engaging macrophages and dendritic cells. The Company’s clinical development programs focus on preventing or treating complications associated with bone-marrow transplantations, Sepsis and solid tumors.
Yep. Won’t surprise if it close red.
Filled Sell 1000 ENLV Limit 8.88 -- -- 12:13:23 10/01/20
they are working hard to keep it under $9
and I have somewhere to go
I got out and watching from sideline. Ready to dive in under 8.
$ENLV lol you reply to a post of mine from June?
Still the same diluting SCAM company regardless of what they hype..I covered that short months ago but went in again today low $12's before the next offering.
ENLV 8.88 but 7.80 is the low on the gap up
lets see
enlv 9.07 AGAIN
UGH~!
what did you do
??
LOL. This is not what I want. Going back to option flipping.
Back in the water one more time. 11.10
11.80 SQUEEZE is on
ENLV
LOL congrats
ENLV
11.11 again on that halt thats my # https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158635323
ENLV VERSUS WHAT RLFTF OTC COMPANY DID ON THIS KINDA NEWS. RLFTF MARKETCAP WENT OVER $1B IN A FEW DAYS SOME MONTHS AGO ON THIS NEWS. GOOD LUCK TO THE ENLV BULLS.
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
78
|
Created
|
04/03/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |